Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Apple Intelligence China Approval Lifts Alibaba and Baidu Shares 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
ATLANTA, Jan. 29, 2016 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the “Company”), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, February 5, 2016 at 9:00 a.m. ET to review the Company’s financial results for the three month period ended December 31, 2015 and provide an update on recent corporate developments. The Company will issue a press release summarizing its financial results the same day, prior to the conference call.
In order to participate in the conference call, please dial (877) 312-5422 (domestic) or (253) 237-1122 (international) and refer to conference ID number 31712361. The live webcast can be accessed under the Investors section of the Company’s website at www.biotapharma.com or you may use the link:
http://edge.media-server.com/m/p/pa9bmsp5.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 1 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Contact: Mark Colonnese Executive Vice President and Chief Financial Officer Biota Pharmaceuticals, Inc. (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
